Practical Approaches to Lymphoma Treatment for Nurses 2018
At the conclusion of this activity, participants will be able to:
- Describe the evolving treatment options for patients with lymphoma;
- Identify challenges associated with chemotherpay adherence and the management of toxicities;
- Discuss approaches to addressing the toxicity of checkpoint inhibitors with lymphoma patients.
Associate Professor of Medicine
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Associate Director for Clinical Services
Rutgers Cancer Institute Medical Director
Oncology Service Line
RWJ Barnabas Health Director, Lymphoma Program
Division of Blood Disorders Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ
Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.